BioNTech
NEWS
Despite the constant need for social distancing, mask-wearing, and the isolation and economic uncertainty that resulted from the outbreak, there is still much to be thankful for when families gather around a virtual table to break bread and carve the turkey this year.
The Pfizer-BioNTech vaccine (now Comirnaty®) was fully approved by the U.S. Food and Drug Administration (FDA) on August 23 and boosters of this shot are now available to the most vulnerable Americans.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 24, 2020.
As expected after Pfizer and BioNTech announced their COVID-19 vaccine Phase III trial had completed and demonstrated a 95% efficacy rate, the companies plan to apply for an Emergency Use Authorization (EUA) with the FDA.
In addition to coming sooner than expected, the results are even better than expected. The trial hit all primary efficacy endpoints.
There are similarities between the two COVID-19 vaccine candidates, and a few differences. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 17, 2020.
The BioNTech scientist said his vaccine can “bash the virus over the head”.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
JOBS
IN THE PRESS